We are live on ! Find out more
CODX

Co-Diagnostics

51 hedge funds and large institutions have $8.06M invested in Co-Diagnostics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

397% more call options, than puts

Call options by funds: $308K | Put options by funds: $62K

0.05% less ownership

Funds ownership: 0.63%0.58% (-0.05%)

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

15% less funds holding

Funds holding: 6051 (-9)

46% less capital invested

Capital invested by funds: $14.8M → $8.06M (-$6.75M)

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

Holders
51
Holders Change
-9
Holders Change %
-15%
% of All Funds
0.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
14
Reduced
15
Closed
14
Calls
$308K
Puts
$62K
Net Calls
+$246K
Net Calls Change
-$454K

CODX Hedge Fund Activity: Q1 2023 in Review

51 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2023, worth a combined $8.06M — down 46% from $14.8M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CODX and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 14 added.

The largest buyer was Morgan Stanley, adding an estimated $412K. The largest seller was Easterly Investment Partners, exiting entirely with an estimated $313K sold.

  • 51 institutional investors held Co-Diagnostics (CODX) as of Q1 2023, down from 60 in Q4 2022.
  • Funds reported $8.06M of Co-Diagnostics stock for Q1 2023, down 46% quarter-over-quarter.
  • 6 funds opened new Co-Diagnostics positions in Q1 2023 and 14 closed out, a net change of -8 holders.
  • The largest Co-Diagnostics buyer in Q1 2023 was Morgan Stanley, an estimated $412K added.
  • The largest Co-Diagnostics seller in Q1 2023 was Easterly Investment Partners, an estimated $313K sold.

Based on aggregated 13F filings for Q1 2023.